Researchers at Retro Biosciences have made significant strides in their mission to extend healthy human lifespans, recently completing a fundraising round that values the company at $1.8 billion. Backed by notable figures like OpenAI CEO Sam Altman, Retro is focused on adding an extra decade of healthy living through innovative approaches, including gene therapies and cell replacement technologies. They are currently conducting their first clinical trial of an oral treatment aimed at improving the clearance of protein aggregates, which are linked to Alzheimer’s disease.

This research is particularly relevant for anyone interested in aging well. If successful, Retro’s therapies could not only address age-related diseases like Alzheimer’s but also enhance overall health, potentially improving memory and cognitive function. The company’s early results from the trial are promising, as they report no serious side effects so far. This could mean that people might have access to new treatments that help maintain their health as they age.

However, it’s important to note that this research is still in its early stages. The current trial is just the beginning, and while the preliminary results are encouraging, we won’t see the full data until August 2026. The findings are still unproven in larger human populations, so it’s too early to draw definitive conclusions about the effectiveness of these therapies. Retro Biosciences is transitioning from basic research to early human testing, which is a crucial step in developing treatments that could prevent and even reverse the effects of aging.

Source: longevity.technology